Biogen’s Alzheimer’s drug Aduhelm
Biogen announces phase 2 data for cutaneous lupus erythematosus
The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
FDA approves Priovant’s Lisraya for dermatomyositis
This is the first oral drug treatment for this rare disease in adults
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Teva submits FDA application for paediatric Tourette syndrome therapy
Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline